Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery

The Polo-like kinase 1 (Plk1) plays a key role in regulating a broad spectrum of critical cell cycle events. Plk1 is a marker of cellular proliferation and has prognostic potential in different types of human tumors. In a series of preclinical studies, Plk1 has been validated as a cancer target. This prompted many pharmaceutical companies to develop small-molecule inhibitors targeting the classical ATP-binding site of Plk1 for anticancer drug development. Recently, FDA has granted a Breakthrough Therapy designation to the Plk inhibitor BI 6727 (volasertib), which provided a survival benefit for patients suffering from acute myeloid leukemia. Remarkably, a new generation of Plk1 inhibitors that target the second druggable domain of Plk1, the Polo-box domain, is currently being tested preclinically. Since various ATP-competitive compounds of Plk1 inhibit also the activities of Plk2 and Plk3, which act as tumor suppressors, the roles of closely related Plk-family members in cancer cells need to be considered carefully. In this article, the authors highlight recent insights into the biology of Plks in cancer cells and discuss the progress in the development of small-molecule Plk1 inhibitors. The authors believe that the greatest therapeutic benefit might come through leukemic cells that are in direct contact with the inhibitor in the blood stream. The identification of biomarkers and studies that document Plk activities in treated patients would also be beneficial to better understand the role of Plk inhibition in tumor development and anticancer therapy.

[1]  C. Linhart,et al.  Prognostic value of pololike kinase expression in melanomas. , 2000, JAMA.

[2]  B. Kuster,et al.  Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells , 2014, Cell Research.

[3]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[4]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[5]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[6]  J. Lazo,et al.  Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype , 2012, Molecular Cancer Therapeutics.

[7]  K. Strebhardt,et al.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. , 2011, The American journal of pathology.

[8]  Valérie Gailus-Durner,et al.  Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells , 2011, Nature communications.

[9]  T. Karn,et al.  Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Strebhardt,et al.  Silencing of mammalian genes by tetracycline-inducible shRNA expression , 2007, Nature Protocols.

[11]  Erich A. Nigg,et al.  Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.

[12]  David M. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[13]  J. Yuan,et al.  Polo-like kinase, a novel marker for cellular proliferation. , 1997, The American journal of pathology.

[14]  K. Strebhardt,et al.  Tumor inhibition by genomically integrated inducible RNAi-cassettes , 2006, Nucleic acids research.

[15]  K. Strebhardt,et al.  Efficient internalization of the polo-box of polo-like kinase 1 fused to an Antennapedia peptide results in inhibition of cancer cell proliferation. , 2002, Cancer research.

[16]  Michael B Yaffe,et al.  Proteomic Screen Finds pSer/pThr-Binding Domain Localizing Plk1 to Mitotic Substrates , 2003, Science.

[17]  Juping Yuan,et al.  A Pan‐Specific Inhibitor of the Polo‐Box Domains of Polo‐like Kinases Arrests Cancer Cells in Mitosis , 2009, Chembiochem : a European journal of chemical biology.

[18]  R. Grobholz,et al.  Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer. , 2000, Pathology, research and practice.

[19]  Fa Liu,et al.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 , 2009, Nature Structural &Molecular Biology.

[20]  W. Dai,et al.  Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. , 2008, Cancer research.

[21]  B. Li,et al.  Human Prk Is a Conserved Protein Serine/Threonine Kinase Involved in Regulating M Phase Functions* , 1997, The Journal of Biological Chemistry.

[22]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[23]  Z. Darżynkiewicz,et al.  Cell Cycle Arrest and Apoptosis Induced by Human Polo-Like Kinase 3 Is Mediated through Perturbation of Microtubule Integrity , 2002, Molecular and Cellular Biology.

[24]  J. Charron,et al.  Role of Plk2 (Snk) in Mouse Development and Cell Proliferation , 2003, Molecular and Cellular Biology.

[25]  Z. Yin,et al.  Thymoquinone blocks pSer/pThr recognition by Plk1 Polo-box domain as a phosphate mimic. , 2013, ACS chemical biology.

[26]  M. Rehli,et al.  Adhesion induced expression of the serine/threonine kinase Fnk in human macrophages , 2000, Oncogene.

[27]  Sven Kappel,et al.  Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1 , 2005, Oncogene.

[28]  K. Döhner,et al.  Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. , 2014, Blood.

[29]  Marc C Nicklaus,et al.  Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1. , 2010, ACS medicinal chemistry letters.

[30]  C. McGowan,et al.  Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways , 2002, Oncogene.

[31]  R. Kaufmann,et al.  Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease , 2002, Journal of cutaneous pathology.

[32]  T. Veenstra,et al.  Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation. , 2006, Molecular cell.

[33]  K. Strebhardt,et al.  Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. , 2008, Chemistry & biology.

[34]  K. Strebhardt,et al.  A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. , 2008, Analytical biochemistry.

[35]  T. Burns,et al.  Silencing of the Novel p53 Target Gene Snk/Plk2 Leads to Mitotic Catastrophe in Paclitaxel (Taxol)-Exposed Cells , 2003, Molecular and Cellular Biology.